MedTrace Logo

Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer

NCT06666582 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2024-10-30

No results posted yet for this study

Summary

Our aim was to evaluate whether second-line treatment with paclitaxel and ramucirumab was associated with improved clinical outcomes compared to other available therapies. This study involved real-world data collection, focusing on the safety and efficacy of therapeutic combinations, administered to patients with pretreated advanced gastric cancer in the Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).

Conditions

  • Gastric Cancer Stage IV
  • Second-line Treatment
  • Ramucirumab Paclitaxel

Interventions

DRUG

Paclitaxel and ramucirumab

Second-line treatment with paclitaxel/ramucirumab vs other regimens

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-01
Primary Completion
2023-03-30
Completion
2024-01-15

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06666582 on ClinicalTrials.gov